A joint trial of the Australasian Leukaemia and Lymphoma Group (ALLG) and the French CLL branch of the French Innovative Leukemia Organization (FILO) evaluating role of Lenalidomide consolidation in patients with Chronic Lymphocytic Leukemia following initial fludarabine, cyclophosphamide and rituximab (FCR) Chemotherapy.

Trial Profile

A joint trial of the Australasian Leukaemia and Lymphoma Group (ALLG) and the French CLL branch of the French Innovative Leukemia Organization (FILO) evaluating role of Lenalidomide consolidation in patients with Chronic Lymphocytic Leukemia following initial fludarabine, cyclophosphamide and rituximab (FCR) Chemotherapy.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Jan 2017

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms CLL6 RESIDUUM
  • Most Recent Events

    • 18 Jan 2017 New trial record
    • 06 Dec 2016 Interim results (n=79) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top